Welcome to the Optimizing AAV Safety Summit: Predict & Monitor AAV Safety Signals to De-Risk Genetic Therapy Development
Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline, the need to administer high doses, the clinical holds placed on gene therapy trials, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose!
In this setting, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology, pharmacology, non-clinical study leads, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays.
Join us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics, Ask Bio, Eli Lilly, Takeda, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies, learn how clinical safety signals have changed how companies are approaching their pipeline progression, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.
"The opportunity to discuss key safety aspects of AAV gene therapy with other experts in the field is a compelling prospect at this time in the development of AAV therapeutics."
President – Therapeutics
World-Class Speaker Faculty Includes:
Associate Professor of Paediatrics
The University of Pennsylvania & The Children’s Hospital of Philadelphia
Chief Executive Officer
Interim Vice President - Clinical Development
Assistant Professor, AAV Gene Therapy
Professor & Chairman, Department of Genetic Medicine
Weill Cornell Medical College